Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus PENBRITIN.
KLEBCIL vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic